ERBB2 and gestational trophoblastic neoplasm: Collectively, these experimental and clinical observations reinforce the biological plausibility of incorporating anti-HER2 strategies in the management of HER2-positive GTN, highlighting the need for dedicated clinical studies in this specific patient population.